Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 9/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1672761 | 0.82 | IGF1R (0.39) | HDAC1HDAC6CYP2D6IGF1R | |
| SCHEMBL1670282 | 0.80 | HDAC1 (0.47) | HDAC1HDAC6ADRB3ADRB2ADRB1 | |
| SCHEMBL31476426 | 0.79 | HDAC1 (0.62) | HDAC1HDAC6ADRB3ADRB2ADRB1 | |
| SCHEMBL1670322 | 0.79 | HDAC1 (0.62) | HDAC1HDAC6ADRB3ADRB2ADRB1 | |
| SCHEMBL16030871 | 0.72 | CYP1A2 (0.55) | HDAC1HDAC6HDAC8ACHECYP1A2 | |
| SCHEMBL9204868 | 0.72 | ADRB3 (0.59) | HDAC1HDAC6ADRB3ADRB2ADRB1 | |
| SCHEMBL1670237 | 0.70 | HDAC1 (0.49) | HDAC1HDAC6ADRB3ADRB2ADRB1 | |
| SCHEMBL20858899 | 0.70 | ADRB3 (0.52) | HDAC1HDAC6ADRB3ADRB2ADRB1 | |
| SCHEMBL4975930 | 0.70 | CHRM2 (0.56) | HDAC1HDAC6ADRB3ADRB2ADRB1 | |
| SCHEMBL786870 | 0.68 | HDAC1 (0.62) | HDAC1HDAC6HDAC8HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49080-E1 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2022-05-24 | — | — | US | disclosed |
| US-9895389-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2018-02-20 | — | — | US | disclosed |
| US-20170042925-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2017-02-16 | — | — | US | disclosed |
| US-20150141354-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2015-05-21 | — | — | US | disclosed |
| US-20140274921-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-8828951-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2014-09-09 | — | — | US | disclosed |
| US-8466114-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2013-06-18 | — | — | US | disclosed |
| US-20130017993-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2013-01-17 | — | — | US | disclosed |
| EP-2491029-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2012-08-29 | — | — | EP | disclosed |
| US-20120178680-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2012-07-12 | — | — | US | disclosed |
| US-8163704-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| US-20110171159-A1 | Glycoside Derivatives and Uses Thereof | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| WO-2011048112-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170042925-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | HDAC1 1279/4885HDAC6 636/4885ADRB3 1676/4885 |
| US-20120178680-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | HDAC1 1279/4885HDAC6 636/4885ADRB3 1676/4885 |
| US-20150141354-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | HDAC1 1279/4885HDAC6 636/4885ADRB3 1676/4885 |
| US-20130017993-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | HDAC1 1279/4885HDAC6 636/4885ADRB3 1676/4885 |
| US-20110171159-A1 | Glycoside Derivatives and Uses Thereof | SLC5A1, SLC5A2, SLC2A1 | HDAC1 1279/4885HDAC6 636/4885ADRB3 1676/4885 |
| US-20140274921-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | HDAC1 1279/4885HDAC6 636/4885ADRB3 1676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.